Peak Bio, Inc. (PKBO)
OTCMKTS · Delayed Price · Currency is USD
0.0225
0.00 (0.00%)
Inactive · Last trade price on Nov 14, 2024
Peak Bio Company Description
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.
The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.
Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD).
The company is based in Palo Alto, California.
Peak Bio, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
Contact Details
Address: 4900 Hopyard Road Pleasanton, Delaware Delaware United States | |
| Phone | 925-463-4800 |
Stock Details
| Ticker Symbol | PKBO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US70470P1084 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hoyoung Huh M.D., Ph.D. | Executive Chairman |
| Divya Patel CPA | Acting Chief Financial Officer |
| Dr. Satyajit Mitra Ph.D. | Head of Oncology and Executive Director |